Journal of Shandong University (Health Sciences) ›› 2023, Vol. 61 ›› Issue (5): 11-19.doi: 10.6040/j.issn.1671-7554.0.2022.1081
• 基础医学 • Previous Articles
XIE Xiaoli1,2, QIU Yu1,2, WANG Lijuan1,2
CLC Number:
[1] Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond [J]. Adv Exp Med Biol, 2020, 1248:33-59. doi:10.1007/978-981-15-3266-5_3. [2] Tamura H, Ishibashi M, Sunakawa-Kii M, et al. PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma [J]. Cancers(Basel), 2020, 12(4): 924. [3] 李金花, 庞楠楠, 张正昊, 等. PD-1/PD-L1共刺激分子在慢性淋巴细胞白血病患者中的表达及临床意义[J]. 中华血液学杂志, 2017, 38(3): 198-203. LI Jinhua, PANG Nannan, ZHANG Zhenghao, et al. PD-1/PD-L1 expression and its implications in patients with chronic lymphocytic leukemia [J]. Chinese Journal of Hematology, 2017, 38(3): 198-203. [4] Chen C, Liang C, Wang S, et al. Expression patterns of immune checkpoints in acute myeloid leukemia [J]. J Hematol Oncol, 2020, 13(1): 28. [5] Zeng Z, Yang B, Liao Z. Biomarkers in immunotherapy-based precision treatments of digestive system tumors [J]. Front Oncol, 2021, 11: 650481. doi:10.3389/fonc.2021.650481. [6] Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study [J]. JAMA Oncol, 2019, 5(1): 74-82. [7] Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II study of avelumab in patients with mismatch pepair deficient and mismatch repair proficient recurrent/persistent endometrial cancer [J]. J Clin Oncol, 2019, 37(30): 2786-2794. [8] Desai S, Ansell SM. Future directions in Hodgkin lymphoma: checkpoint inhibitors and beyond [J]. Leuk Lymphoma, 2021, 62(8): 1795-1804. [9] Jaffe ES. Diagnosis and classification of lymphoma: impact of technical advances [J]. Semin Hematol, 2019, 56(1): 30-36. [10] 虞文嫣, 糜坚青. 新免疫治疗时代下复发难治性霍奇金淋巴瘤治疗新策略[J]. 中华血液学杂志, 2019, 40(4): 348-352. YU Wenyan, MI Jianqing. Novel treatment strategies for relapsed and refractory Hodgkin lymphoma in immunotherapy era [J]. Chinese Journal of Hematology, 2019, 40(4): 348-352. [11] Salmaninejad A, Khoramshahi V, Azani A, et al. PD-1 and cancer: molecular mechanisms and polymorphisms [J]. Immunogenetics, 2018, 70(2): 73-86. [12] Cha JH, Chan LC, Li CW, et al. Mechanisms controlling PD-L1 expression in cancer [J]. Mol Cell, 2019, 76(3): 359-370. [13] Chen Q, Li T, Yue W. Drug response to PD-1/PD-L1 blockade: based on biomarkers [J]. Onco Targets Ther, 2018, 11: 4673-4683. doi: 10.2147/ott.s168313. [14] Chen BJ, Dashnamoorthy R, Galera P, et al. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma [J]. Oncotarget, 2019, 10(21): 2030-2040. [15] Zhang XW, Bi XW, Liu PP, et al. Expression of PD-L1 on monocytes is a novel predictor of prognosis in natural killer/T-cell lymphoma [J]. Front Oncol, 2020, 10: 1360. doi: 10.3389/fonc.2020.01360. [16] Hollander P, Amini RM, Ginman B, et al. Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma [J]. PLoS One, 2018, 13(9): e0204870. [17] Xie M, Huang X, Ye X, et al. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma [J]. Int Immunopharmacol, 2019, 77: 105999. doi: 10.1016/j.intimp.2019.105999. [18] Zhang M, Ding G, Zhou L, et al. Interferon gamma inhibits CXCL8-Induced proliferation and migration of pancreatic cancer BxPC-3 cell line via a RhoGDI2/Rac1/NF-κB signaling pathway [J]. J Interferon Cytokine Res, 2018, 38(9): 413-422. [19] Qian J, Wang C, Wang B, et al. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy [J]. J Neuroinflammation, 2018, 15(1): 290. [20] Zhao R, Song Y, Wang Y, et al. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway [J]. Cell Prolif, 2019, 52(3): e12571. [21] Qian J, Wang C, Wang B, et al. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy [J]. J Neuroinflammation, 2018, 15(1): 290. [22] Zhang X, Zeng Y, Qu Q, et al. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer [J]. Int J Clin Oncol, 2017, 22(6): 1026-1033. [23] Xue W, Li W, Zhang T, et al. Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway [J]. Onco Targets Ther, 2019, 12: 2079-2088. doi: 10.2147/ott.s187280. |
[1] | LI Tao, YANG Chunlin, DU Tong, LI Heng, WANG Congcong, LI Xiaoli, DUAN Ruisheng,ZHANG Peng. Effects of diabetes mellitus on the subsets and function of NK cells in myasthenia gravis [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 31-36. |
[2] | LI Honghao, YU Jing, CHEN Yali, GUO Shougang. Evaluation of CD4+CD25+FoxP3+ regulatory T cells and FoxP3 mRNA expression in 20 NMOSD patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 50-54. |
|